PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL- A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS
Abstract
Authors
S Van Sanden N Perualila J Diels N Trevor H Pei J Anjo